New hope for Hard-to-Treat cancers: targeted drug enters human testing
NCT ID NCT07134998
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called HRS-6093 in people with advanced solid tumors that have a specific mutation called KRAS G12D. The study aims to find a safe dose and see how the drug affects the body. About 153 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-6093
- What this could lead to
- If successful, this could lead to a new targeted treatment option for people with advanced cancers that have a specific KRAS G12D mutation.
- What could go wrong
- This is a very early Phase 1 trial with only 153 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.